Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)
Status:
Suspended
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
- Replacement of intrathecal Triple (methotrexate, cytarabine, prednisolone) with
intrathecal liposomal cytarabine and prednisolone during maintenance therapy will
decrease the CNS relapse rate in high-risk ALL patients.
- Both acute and long-term toxicity are equal in both treatment arms.
Phase:
Phase 3
Details
Lead Sponsor:
Nordic Society for Pediatric Hematology and Oncology